Programmed death ligand 2 in cancer-induced immune suppression.
Publication year
2012Source
Clinical & Developmental Immunology, 2012, (2012), pp. 656340ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Tumorimmunology
Medical Oncology
Journal title
Clinical & Developmental Immunology
Volume
vol. 2012
Page start
p. 656340
Page end
p. 656340
Subject
NCMLS 2: Immune RegulationAbstract
Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed and are undergoing human clinical testing. However, PD-L2 has not received as much attention and its role in modulating tumor immunity is less clear. Here, we review the literature on the immunobiology of PD-L2, particularly on its possible roles in cancer-induced immune suppression and we discuss the results of recent studies targeting PD-L2 in cancer.
This item appears in the following Collection(s)
- Academic publications [202652]
- Electronic publications [100827]
- Faculty of Medical Sciences [79967]
- Open Access publications [69558]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.